Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Net Cash Flow (2017 - 2025)

Aclaris Therapeutics has reported Net Cash Flow over the past 9 years, most recently at -$5.3 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$5.3 million for Q4 2025, up 77.05% from a year ago — trailing twelve months through Dec 2025 was -$4.6 million (up 69.89% YoY), and the annual figure for FY2025 was -$4.6 million, up 69.89%.
  • Net Cash Flow for Q4 2025 was -$5.3 million at Aclaris Therapeutics, down from -$146000.0 in the prior quarter.
  • Over the last five years, Net Cash Flow for ACRS hit a ceiling of $78.2 million in Q2 2021 and a floor of -$59.8 million in Q3 2021.
  • Median Net Cash Flow over the past 5 years was -$2.3 million (2023), compared with a mean of -$1.4 million.
  • Biggest five-year swings in Net Cash Flow: soared 465.24% in 2021 and later tumbled 2854.3% in 2024.
  • Aclaris Therapeutics' Net Cash Flow stood at -$26.3 million in 2021, then soared by 37.62% to -$16.4 million in 2022, then skyrocketed by 105.12% to $838000.0 in 2023, then tumbled by 2854.3% to -$23.1 million in 2024, then surged by 77.05% to -$5.3 million in 2025.
  • The last three reported values for Net Cash Flow were -$5.3 million (Q4 2025), -$146000.0 (Q3 2025), and -$5.0 million (Q2 2025) per Business Quant data.